Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 29, 2011

Two-to-One Majority Differs with European Court Ruling Against Patenting hESCs

  • While Europe’s highest court recently ruled that stem cell research based on the destruction of human embryos is contrary to morality and cannot be patented, a nearly two-to-one majority of those who took our poll disagree. Sixty four percent sided with Oliver Brüstle, Ph.D., who since 2004 has fought a challenge from Greenpeace in trying to maintain a 1997 patent covering methods for deriving neural cells from hESCs. Of the respondents, 34% agreed with the court decision, while 5.7% were undecided.

    In its decision, the Court of Justice of the European Union sided with Greenpeace as well as arguments by its advocate general in ruling that: “An invention must be regarded as unpatentable, even if the claims of the patent do not concern the use of human embryos, where the implementation of the invention requires the destruction of human embryos.”

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »